Drugs / Nivolumab-IRDye800
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07210632 | Mar 2026 → Mar 2030 expected | brain cancer, malignant glioma | Eben Rosenthal | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nivolumab-IRDye800 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07210632 ↗ |
| Known as | nivo800 | “Participants will receive an infusion of nivolumab-IRDye800 (nivo800). Nivo800 has never been assessed in patients before and therefore Cohort 1 will receive only a test dose...” NCT07210632 ↗ |